AMENDMENTS TO THE CLAIMS

1. – 36. (cancelled).

37. (currently amended) A quinuclidine derivative represented by Formula I



(I)

an enantiomer thereof, or a mixture of its enantiomers, or a pharmaceutically-acceptable addition salt thereof, or an onium salt thereof, wherein,

------ represents an optional double bond;

n is 2 ~~1, 2 or 3~~;

X represents the linker –O– ~~a linker selected from –O–, –O–CH$_2$–, –O–CH$_2$–CH$_2$–, –S–, –SO–, –SO$_2$–, –CH$_2$–, –S–CH$_2$–CH$_2$–, –CH$_2$–, –C(=CH$_2$)–, –NH–, –N(alkyl)–, –C(=O)–, –C(=S)–,~~



;

~~and~~



; and

A represents a pyridazinyl ~~monocyclic or polycyclic, carbocyclic or heterocyclic~~ group, optionally substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, CF_3, CN, NO_2, NH_2, carboxy, carbamoyl, amido, sulfamoyl, and phenyl, or with another monocyclic or polycyclic, carbocyclic or heterocyclic group, which additional monocyclic or polycyclic, carbocyclic or heterocyclic group may optionally be substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, CF_3, CN, NO_2, NH_2, carboxy, carbamoyl, amido, sulfamoyl, and phenyl~~; provided, however, if X represents O or S; then A is not phenyl or phenyl substituted with anything other than a phenyl group~~.

38. (previously presented) The quinuclidine derivative of claim 37, wherein ------ represents a single (covalent) bond.

39. -44. (cancelled).

45. (currently amended) The quinuclidine derivative of claim 37, wherein A represents ~~a monocyclic heterocyclic group selected from pyridyl, in particular pyrid-2-yl, pyrid-3-yl and pyrid-4-yl; thienyl, in particular thien-2-yl and thien-3-yl; furanyl, in particular furan-2-yl and furan-3-yl; pyridazinyl, in particular pyridazin-3-yl and pyridazin-4-yl; thiazolyl, in particular thiazol-2-yl, thiazol-4-yl and thiazol-5-yl; thiadiazolyl, in particular 1,3,4-thiadiazol-2-yl, 1,3,4-thiadiazol-5-yl, 1,2,4-thiadiazol-3-yl and 1,2,4-thiadiazol-5-yl; which monocyclic heterocyclic~~ pyridazinyl, which pyridazinyl group is optionally substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, alkoxy, cycloalkoxy, halo, CF_3, CN, NO_2, NH_2, phenyl, 2-thienyl, 3-thienyl, 2-furanyl, 3-furanyl, and 3-pyridinyl, which phenyl, 2-thienyl, 3-thienyl, 2-furanyl, 3-furanyl, and 3-pyridinyl groups may optionally be substituted one or two times with substituents selected from the group consisting of alkyl, cycloalkyl, alkoxy, halo, CF_3, CN, NO_2, NH_2, and phenyl.

46. (currently amended) The quinuclidine derivative of claim 45, which is

~~(±) 3-(3,4,5-Trichloro-thien-2-yloxy)-1-aza-bicyclo[2.2.2]octane;~~

~~(±) 3-(5-Bromo-thiazol-2-yloxy)-1-aza-bicyclo[2.2.2]octane;~~

~~(±) 3-(5-Phenyl-thiazol-2-yloxy)-1-aza-bicyclo[2.2.2]octane;~~

~~(±) 3-[5-(2,4-Difluoro-phenyl)-thiazol-2-yloxy]-1-aza-bicyclo[2.2.2]octane;~~

~~(±) 3-[5-(3-Thienyl)-thiazol-2-yloxy]-1-aza-bicyclo[2.2.2]octane;~~

~~(±) 3-[5-(2-Thienyl)-thiazol-2-yloxy]-1-aza-bicyclo[2.2.2]octane;~~

~~(±) 3-[5-(3-Furanyl)-thiazol-2-yloxy]-1-aza-bicyclo[2.2.2]octane;~~

~~(±) 3-[5-(3-Pyridyl)-thiazol-2-yloxy]-1-aza-bicyclo[2.2.2]octane;~~

(±)-3-(6-Chloro-pyridazin-3-yloxy)-1-aza-bicyclo[2.2.2]octane;

(±)-3-(6-Bromo-pyridazin-3-yloxy)-1-aza-bicyclo[2.2.2]octane;

(±)-3-(6-Phenyl-pyridazin-3-yloxy)-1-aza-bicyclo[2.2.2]octane;

(±)-3-[6-(3-Thienyl)-pyridazin-3-yloxy]-1-aza-bicyclo[2.2.2]octane;

(±)-3-[6-(2-Thienyl)-pyridazin-3-yloxy]-1-aza-bicyclo[2.2.2]octane;

(±)-3-[6-(2-Furanyl)-pyridazin-3-yloxy]-1-aza-bicyclo[2.2.2]octane;

(±)-3-[6-(3-Furanyl)-pyridazin-3-yloxy]-1-aza-bicyclo[2.2.2]octane; or

(±)-3-[6-(3-Pyridyl)-pyridazin-3-yloxy]-1-aza-bicyclo[2.2.2]octane;

~~(±)-3-(5-Phenyl-1,3,4-thiadiazol-2-yloxy)-1-aza-bicyclo[2.2.2]octane;~~

~~(±)-3-(5-Phenyl-1,2,4-thiadiazol-3-yloxy)-1-aza-bicyclo[2.2.2]octane; or~~

~~(±)-3-[5-(2-Thienyl)-1,3,4-thiadiazol-2-yloxy]-1-aza-bicyclo[2.2.2]octane;~~

or an enantiomer thereof, or a pharmaceutically-acceptable addition salt thereof, or an onium salt thereof.

47. – 55. (cancelled).

56. (previously presented) A pharmaceutical composition comprising a therapeutically effective amount of a quinuclidine derivative of claim 37, or a pharmaceutically-acceptable addition salt thereof.

57. – 65. (cancelled).